BusinessWire has been designated by BioNJ as its preferred distributor of news releases to the life sciences news media and investment community.

• Protalex Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee
  SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its independent Data Safety Monitoring Committee, the Company is continuing enrollment and increasing the dose for subjects in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-10
• Mayo Clinic Forms Joint Venture with Cancer Genetics
  RUTHERFORD, N.J.--(BUSINESS WIRE)--Cancer Genetics and Mayo Clinic partner to create OncoSpire Genomics with the goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing
• NPS Pharmaceuticals Prices Public Offering of Common Stock
  BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being sold by NPS. The gross proceeds to NPS from this offering are expected to be approximately $87.2 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by NPS. The offering is expected to cl
• Merck Announces $5 Billion Accelerated Share Repurchase
  WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck has entered into an accelerated share repurchase agreement (ASR) with Goldman, Sachs & Co. to repurchase $5 billion of Merck’s common stock.
• Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for Diversity Alliance for Science
  SECAUCUS, N.J.--(BUSINESS WIRE)--Caligor Rx, a leader in the global procurement of comparator drugs for clinical trials worldwide, today announced that Managing Director Tammy Bishop has been elected to the Board of Directors for Diversity Alliance for Science (DA4S), a national organization that fosters supplier diversity within the life sciences industry. “It is a privilege to join the board of DA4S, and I look forward to contributing my knowledge and experience to help the organization achiev
• Cordis Showcases Cardiovascular Innovations at EuroPCR 2013
  FREMONT, Calif.--(BUSINESS WIRE)--Cordis Corporation will introduce the two latest additions to its portfolio of cardiovascular solutions at EuroPCR 2013, 21-24 May: S.M.A.R.T.® Flex Vascular Stent System and ADROIT Guiding Catheter
• Cancer Genetics to Attend ASCO Annual Meeting
  RUTHERFORD, N.J.--(BUSINESS WIRE)--Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will attend for the first time the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting on May 31-June 4, 2013 at McCormick Place in Chicago. CGI will be at stand number 19120 during the event. The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties to discuss challenges and dev
• NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common Stock
  BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares in the offering are to be sold by NPS. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the proposed offering. NPS intends to grant the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock to cover
• STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
  PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS has treated the first heart attack patient in a U.S. clinical trial to compare the STENTYS Self-Apposing Stent to the Abbott Multi-Link Stent at one year post-procedure.
• Merck to Present at the UBS Global Healthcare Conference
  WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced today that Peter N. Kellogg, exec vp and chief financial officer, Merck, is scheduled to present at the UBS Global Healthcare Conf in New York City on May 20, 2013 at 10:30 a.m EDT.